CD34+ CP CML MNCs were significantly more sensitive to TKIs than CD34- MNCs (Figure 7A), which was most pronounced with the more potent TKIs dasatinib and ponatinib. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.